Estudo randomizado | Nivolumabe com quimioterapia vs. quimioterapia isolada para adenocarcinomas esofágico, de junção gastresofágica e gástrico avançados.

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Comentário no Twitter (fio – clique para sair mais)

#Nivolumab plus chemotherapy shows superior OS, PFS benefit, and acceptable safety profile—compared to chemotherapy alone—in previously untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma.

🔗 https://t.co/0u9R5ZIwd2, by @YJanjigianMD et al.

— The Lancet (@TheLancet) July 8, 2021